logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis : experience from rural South Africa.

    Article - En anglais

    Objective 

    To conduct an economic evaluation of directly observed treatment (DOT) and conventionally delivered treatment for the management of new cases of tuberculosis in adults.

    Design 

    Community based directly observed treatment, which has been implemented in the Hlabisa district of South Africa since 1991, was compared with a conventional approach to tuberculosis treatment widely used in Africa Each was assessed in terms of cost, cost effectiveness, and feasibility of implementation within existing resource constraints.

    Setting 

    Hlabisa Health District, South Africa.

    Subjects 

    Adult patients with new cases of tuberculosis on smear testing ; the number of cases increased from 20 per month to over 100 from 1991 to 1996.

    Main outcome measures 

    Cost of case management in 1996, cost effectiveness in terms of the cost per case cured, and bed requirements in comparison with bed availability for the 1990,1993, and 1996 caseload.

    Costs are expressed in US dollars at values for 1996.

    Results 

    Directly observed treatment was 2.8 times cheaper overall than conventional treatment ($740.90 compared with $2047.70) to deliver.

    Directly observed treatment worked out 2.4-4.2 times more cost effective, costing $890.50 per patient cured compared with either $2095.60 (best case) or $3700. (...)

    Mots-clés Pascal : Tuberculose, Mycobactériose, Bactériose, Infection, Mycobacterium tuberculosis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bactérie, Analyse coût efficacité, Traitement, Economie santé, Chimiothérapie, Antituberculeux, Zone rurale, Homme, République Sud Africaine, Afrique

    Mots-clés Pascal anglais : Tuberculosis, Mycobacterial infection, Bacteriosis, Infection, Mycobacterium tuberculosis, Mycobacteriaceae, Mycobacteriales, Actinomycetes, Bacteria, Cost efficiency analysis, Treatment, Health economy, Chemotherapy, Antituberculous agent, Rural area, Human, South Africa, Africa

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0032648

    Code Inist : 002B02S02. Création : 17/04/1998.